Algeria Pharmaceutical Market Analysis Sample Report

Algeria
Pharmaceutical
Market Analysis
A sample report on
Includes Market Size, Market Segmented by
Types and Key Competitors (Data forecasts
from 2023 – 2030F)
www.insights10.com

This report presents a strategic analysis of the Algeria
Pharmaceutical Market and a forecast for its development in
the medium and long term. It provides a comprehensive
overview of the market value, dynamics, segmentation, main
players, growth and demand drivers, challenges & future
outlook, etc. This is one of the most comprehensive reports
about the Algeria Pharmaceutical Market, and offers
unmatched value, accuracy, and expert insights.

3
A Sample Report on Algeria Pharmaceutical Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Pharmaceutical Overview 06-19
1.1. Overview
1.2. Algeria Overview
1.3. Economic Overview: Algeria
1.4. Pharmaceutical Market in Algeria
1.5. Pharmaceuticals Market in Algeria
1.6. Healthcare Scenario in Algeria
1.7. Health Insurance Coverage: Algeria
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 20-26
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
3. Market Dynamics 27-31
3.1. Market Growth Drivers
3.2. Market Restraints
4. Competitive Landscape 32-42
4.1. Major Market Share
4.2. Key Company Profile
5. Reimbursement Scenario 43-48
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
6. Methodology & Scope 49-54

Algeria Pharmaceutical Market Analysis
1. Pharmaceutical Overview

7
1.1 Statistics at a Glance: Pharmaceutical Market in the World
▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
13.4%
Market share was for
the drug Humira in
2022
Covid-19
Had a major market share in
the pharmaceutical market in
2022
55 years
Is the average age of patient
taking medicine of major market
share
$2499.23 Bn
Is the projected global
sales figure for
pharmaceutical market by
2030
US
Is the largest
market for drugs in
2022

8
1.1 Statistics at a Glance: Pharmaceutical Market in the World (continued)
North America
~ Market Size of
$675.13 Bn
Europe
~Revenue to reach
$432.40 Bn by
2030
Asia
-Fastest CAGR
Africa
~Market Size of
$20.25 Bn
Algeria
~$2.7 Bn Market
Illustrative

9
1.2 Algeria Overview
43.45 Mn
Is the population of
Algeria, in 2022
31.3 years
Is the median age
in Algeria, in 2022
269.2 Bn
Is the Gross
Domestic Product
(GDP) in Algeria in
2022
$292
Per capita was the
amount of national
health expenditures in
2022
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

10
1.3 Economic Overview: Algeria
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Algeria, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Algeria, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

11
1.4 Statistics at a Glance: Pharmaceutical Market in Algeria
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Algeria
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
25%
Market share was for
the drug Paracetamol
in 2022
Hypertension
Had a major market share in
the pharmaceutical market in
2022
70%
Of the medicine in
Algeria was imported in
2022
$2.7 Bn
Is the global figure for the
pharmaceutical market in
2022

12
1.5 Healthcare Scenario in Algeria
▪ Healthcare Infrastructure: Algeria has a public healthcare system that provides free or low-cost healthcare services to its citizens. The
country has a network of hospitals, clinics, and healthcare centers, both in urban and rural areas. However, the healthcare infrastructure in
rural areas may be limited compared to urban areas
▪ Healthcare Funding: The Algerian government allocates a significant portion of its budget to the healthcare sector. The funding is primarily
used to support the operation of public healthcare facilities, purchase medical equipment, and provide essential medications
▪ Universal Healthcare Coverage: Algeria has implemented a system of universal healthcare coverage, known as the "Caisse Nationale
d'Assurance Maladie" (CNAS). The CNAS provides access to healthcare services for the entire population, including employed and
unemployed individuals, as well as their dependents
▪ Public and Private Sector: The healthcare sector in Algeria consists of both public and private healthcare providers. Public healthcare
facilities are generally more accessible and affordable for the majority of the population. However, private healthcare facilities exist,
particularly in urban areas, and offer services to those who can afford them
▪ Health Challenges: Algeria, like many other countries, faces various health challenges. Some of the common health issues in Algeria
include cardiovascular diseases, diabetes, obesity, respiratory diseases, and cancer. The government has been working on improving
healthcare infrastructure, implementing disease prevention programs, and promoting healthier lifestyles
▪ Healthcare Workforce: Algeria has a significant number of healthcare professionals, including doctors, nurses, and specialists. However,
there may be regional disparities in the distribution of healthcare professionals, with urban areas having more resources compared to rural
regions
▪ Pharmaceutical Industry: Algeria has a domestic pharmaceutical industry that produces a range of medications. The government
encourages the local production of essential drugs to ensure their availability and affordability for the population. Additionally, Algeria also
imports pharmaceutical products from other countries

13
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

14
1.7 Health Insurance Coverage: Algeria
1.0
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Private (18.9%), Public (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

15
1.8 Budget of Algeria Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Public
$769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
$458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Public spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Private spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

16
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

17
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Algerian Ministry of
Health collaboration
with Novartis
Collaboration - May, 2022
▪ Collaboration will focus on developing a national plan for the
prevention and control of non-communicable diseases (NCDs)
▪ Collaboration will aim to reduce the prevalence of NCDs by 25%
by 2030
▪ It is a partnership between the public and private sectors, and it is
expected to have a major impact on the health of the Algerian
population
Hikma acquisition of
Pharma 5
Acquisition $250 Mn March 2022
▪ Acquisition will give Hikma a strong foothold in the Algerian
pharmaceutical market, which is the largest in North Africa
▪ Hikma expects the acquisition to be accretive to earnings in the
first full year of ownership
▪ Acquisition of Pharma 5 is a significant move by Hikma as it looks
to expand its presence in the Middle East and North Africa
(MENA) region. The MENA region is a growing market for generic
medicines, and Hikma is well-positioned to capitalize on this
growth
Latest Deals In Algeria

18
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Algeria

2. Market Size and Forecasting

20
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Algeria Pharmaceutical Market Forecast, 2022-2030 (in $Bn)
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Algeria Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Algeria Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

21
2.2 Snapshot of Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Algeria Pharmaceutical Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Brand
Domestic Brands
International Brands
Therapeutic Area
Oncology
Central nervous
system
Pain management
Cardiovascular
Respiratory
Diabetes
Gastrointestinal
Anti-infectives
Others
Distribution Channel
Hospitals
Pharmacies
Retail outlets
Online retailers

22
Algeria Pharmaceutical Market Share, By Brand (2022)
Domestic
Brands, 45%
International
Brands, 55%
final report
2.2.1 Market Segmentation: By Brand
Illustrative

23
Algeria Pharmaceutical Market Share, By Therapeutic Area (2022)
Oncology
Central Nervous
System
Pain
Management
Cardiovascular
Respiratory
Diabetes
Gastrointestinal
Anti-Infectives
Others
2.2.2 Market Segmentation: By Therapeutic Area
final report
Illustrative

24
Algeria Pharmaceutical Market Share, By Distribution Channel
(2022)
Hospitals
Pharmacies
Retail
Pharmacies
Online Retailers
2.2.3 Market Segmentation: By Distribution Channel
final report
Illustrative

3. Market Dynamics

26
3.1 Market growth drivers
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
▪ In order to obtain access to all of the information that you
are seeking, you will need to purchase the final report
include data, analysis, trends, and other relevant
information related to the topic or subject matter of interest
2010 2022 2030
3.1.1 Prevalence of chronic diseases is increasing in Algeria, according to WHO Cardiovascular diseases and
Diabetes are the leading cause of death which accounts for around 31% and 14% of total deaths respectively in
Algeria
Prevalence of Chronic Diseases in
Algeria

27
3.1 Market growth drivers (continued)
Top countries that are investing in
development of generic drugs
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 Growing Demand for generic drugs, market share of generic drugs in Algeria accounts for around 75% of the
total pharmaceutical market

28
3.1 Market growth drivers (continued)
Fundings from the government and other
organizations
3.1.3 Government initiatives and support, the Algerian government has provided tax exemption and subsidy for the
production of generic drugs and funding for the development of generic drugs
Source Year Fund ($)
National Cancer
Institute (NCI)
2021 $ 6.4 Bn
Centers for Disease
Control and
Prevention (CDC)
2021 $ 501 Mn
American Cancer
Society (ACS)
2020 $ 150 Mn
Susan G. Komen 2020 $ 98 Mn

29
3.2 Market restraints
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
3.2.1 Complex regulatory system,
which increases entry barriers for
foreign pharmaceutical
companies
3.2.3 Lack of skilled professionals
in Algeria for pharmaceutical
companies, which makes it difficult
to hire qualified employees
3.2.2 Limited access to credit,
Algerian banks are reluctant to
give loans to pharmaceutical
companies
▪ Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪ In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
▪ Final report will be
comprehensive and detailed, and
it will include data, analysis,
trends, and other relevant
report
report

4. Competitive Landscape

31
4.1 Major Market Share
XX
Other
report
interest
Revenue of Major Players in Algeria Pharmaceutical
Market ($ Mn)
Illustrative

32
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Saidal
3 Sotex
5 AstraZeneca
7 Novartis
9 Abbott
2 Sanofi-Aventis
4 Pfizer
6 Servier
8 MSD
Johnson & Johnson
10
Key Note:

33
4.2.1 Saidal
Founded in: 1982
HQ: Algiers, Algeria
Type: State-owned
Revenue: $1.2 Bn
Website: www.saidalgroup.
▪ Saidal is the largest pharmaceutical company in Algeria and one
of the largest in Africa
▪ In recent years, Saidal has been expanding its production
capacity and investing in research and development
▪ It has also been expanding its export markets
▪ Saidal is well-positioned to continue to grow in the coming years
Solutions offered by Saidal
➢ Generic Drugs
➢ Over-the-Counter Drugs
➢ Vaccines
➢ Clinical Trials
➢ Research and Development
Drugs
Antibiotics Anti-Inflammatory
Anti-Cancer Decongestants
Pain relivers Sleep aids
Digestive aids Allergy Medications
Drugs for Cancer Recent Activity / Press Coverage
In 2023, Saidal announced that it would be investing in a new research and
development center
In 2022, Saidal launched its first bioequivalence center
Saidal is also expanding its production capacity in order to meet the growing
demand for its products

34
4.2.1 Saidal (continued)
Partnership was initially focused on developing and marketing generic drugs in Algeria. However, it has since
expanded to include other areas, such as developing new drugs and transferring technology
Saidal Pharmaceuticals and Sinovac Biotech have a partnership to produce the Sinovac COVID-19 vaccine in
Algeria. The partnership between Saidal and Sinovac is a significant development for the pharmaceutical
industry in Algeria. It will help to ensure that Algeria has a stable supply of the Sinovac vaccine, and it will also
help to promote research and development in the pharmaceutical sector.
Saidal Pharmaceuticals and Biocad have a partnership to produce the Sputnik V COVID-19 vaccine in
Algeria. In addition to the Sputnik V vaccine, Saidal and Biocad are also working on the development of other
vaccines, including a vaccine against the Zika virus
Partnership Ecosystem

35
Company Name Type Year Key Pointers
Pfizer
Collaboration
December,
2022
▪ The partnership between Saidal and Pfizer is a major development for
the pharmaceutical industry in Algeria
▪ It will help to ensure that Algeria has a stable supply of the Pfizer-
BioNTech vaccine, and it will also help to promote research and
development in the pharmaceutical sector
▪ In addition to the Pfizer-BioNTech COVID-19 vaccine, Saidal and Pfizer
are also working on the development of other vaccines, including a
vaccine against the Zika virus
Laboratoires du Sud
Acquisition March 2022
▪ Laboratoires du Sud is a leading pharmaceutical company in Algeria,
with a strong presence in the generic drug market
▪ Acquisition will give Saidal access to Laboratoires du Sud's
manufacturing facilities, product portfolio, and distribution network
▪ This will help Saidal to strengthen its position in the Algerian
pharmaceutical market and expand its reach into new markets.
Laboratoires du Sud has a strong R&D department, and the acquisition
will give Saidal access to new technologies and expertise
Latest Deals - Mergers and Acquisitions

36
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

37
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage

38
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem

39
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions

40
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4

5. Reimbursement Scenario

42
5.1 Reimbursement Regulation
The reimbursement scenario in the Algerian market is complex and can vary
depending on the specific treatment, setting of care, and insurance coverage.
Here are some key points to consider:
▪ Public:
o Public is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Public covers many cancer treatments, including chemotherapy,
radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Private:
o Private is a joint federal-state program that provides health insurance
for people with low incomes
o Private coverage for cancer treatments can vary by state and may be
subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Public and Private together provide
health insurance coverage for more than
4 in 10 Algerians
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

43
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

44
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Public and Private
 Public is a federal program that provides healthcare coverage to individuals who are
65 years of age or older, as well as certain younger people with disabilities
 Private is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the Algerian healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

45
5.2 Reimbursement Process for Diagnosis
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

46
5.3 Reimbursement Process for Treatment
The reimbursement process in the US healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Algeria Pharmaceutical Market Analysis Sample Report

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Algeria Pharmaceutical Market Analysis Sample Report

Similar to Algeria Pharmaceutical Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Algeria Pharmaceutical Market Analysis Sample Report